Adagene Inc (ADAG) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Adagene Inc stock $1.40, price $1.60, that is 12.5% below the price, quality 40 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Adagene Inc
ADAG · USExpensive (fair value 13% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range $0.9000 – $18.55 · fair‑value band $1.05 – $1.75 · the $1.60 price screens above the $1.40 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Adagene is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China.
Show moreShow less
Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development.
In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors.
Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Stock analysis
Adagene Inc (ADAG) currently trades at $1.60, while our estimate is $1.40, 13% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $1.05 (bear) to $1.75 (bull), the price of $1.60 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Adagene Inc reported revenue of $7.7M in FY2025 versus $10.2M in FY2021, a compound −6.8%/yr. Reported net income was −$17.6M in FY2025.
Key figures
Market cap $162M Micro · P/S ratio 17.4 · EPS (TTM) $−0.3800 · Return on equity −28.5% · Return on assets (EBIT) −36.3% (5-year average) · Operating margin −1,024% · Revenue (TTM) $9.3M · Revenue growth (YoY) +73.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 67% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −13%, ADAG screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 3 officers or directors bought shares worth $162,258, most recently on Sep 23, 2026. Buying cluster
- BuyMan Kin TamChief Financial Officer, Director2,000 shares at $3.00$6,000Sep 23, 2026
- BuyPeter LuoChief Executive Officer, Director2× since Aug 4, 2026: 43,535 shares, avg. $3.42$148,758Sep 16, 2026
- BuyCuong Do VDirector2,000 shares at $3.75$7,500Aug 14, 2026
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Adagene Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Price/FCF by industry
- Debt-to-equity by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs ADAG |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs ADAG |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs ADAG |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs ADAG |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs ADAG |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs ADAG |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs ADAG |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs ADAG |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs ADAG |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs ADAG |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Adagene Inc (ADAG) overvalued or undervalued?
What is the fair value of ADAG?
What is the quality score of ADAG?
What is the price target for Adagene Inc (ADAG)?
What is the Adagene Inc stock forecast for 2026?
What is the revenue of Adagene Inc (ADAG)?
What is the intrinsic value of Adagene Inc (ADAG)?
Is Adagene Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of ADAG?
How much is Adagene Inc worth?
What do the bullish and bearish scenarios say about ADAG?
How solid is the balance sheet of Adagene Inc (ADAG)?
How far is ADAG from its 52-week high?
Which stocks are comparable to Adagene Inc?
Is Adagene Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Adagene Inc (ADAG)?
What should I pay attention to with Adagene Inc right now?
Key figures of Adagene Inc
How large is the market capitalisation of Adagene Inc (ADAG)?
What is the P/S ratio of Adagene Inc (ADAG)?
What are the earnings per share of Adagene Inc (ADAG)?
What is the return on equity of Adagene Inc (ADAG)?
What is the EBIT return on assets of Adagene Inc (ADAG)?
What is the operating margin of Adagene Inc (ADAG)?
How fast is revenue growing at Adagene Inc (ADAG)?
How much free cash flow does Adagene Inc (ADAG) generate?
How much net cash does Adagene Inc (ADAG) hold?
Watch Adagene Inc in the live analysis
One click puts Adagene Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.